Trial Profile
Single-arm retrospective study to identify chronic refractory urticaria patient phenotypes predictive of omalizumab response.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 02 May 2014 New trial record